EpiVax AI Models Enhance Immunogenicity Risk Assessment

EpiVax has launched new AI-enhanced models for its ISPRI platform. These updates improve the assessment of immunogenicity risk for biotherapeutics. The release includes an updated JanusMatrix model, a refined tolerance-adjusted immunogenicity score, and an enhanced anti-drug antibody prediction model. JanusMatrix 2.1 uses AI to predict immune tolerance more precisely. The new JanusMatrix-Adjusted EpiMatrix score, or JAX score, aims for better alignment with clinical immunogenicity outcomes. Additionally, ADA 2.2 combines epitope-based measures with biophysical attributes to predict antibody immunogenicity risk. These new features strengthen EpiVax's capabilities and align with FDA initiatives for New Approach Methodologies. This helps identify immune liabilities and de-risk development programs.